Shopping Cart 0
Cart Subtotal
USD 0

Cadila Healthcare Ltd (CADILAHC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cadila Healthcare Ltd (Zydus Cadila) is an integrated, global healthcare provider. It discovers, develops, manufactures and markets various healthcare products. The company's product portfolio includes active pharmaceutical ingredients (APIs), formulations, wellness and animal health products. Zydus Cadila's products find application in the treatment of diseases in the therapeutic areas of gastrointestinal, cardiovascular, respiratory, pain management, cancer, inflammation, neurology, and women's health, among others. It conducts research to develop biologics, vaccines and new chemical entities. The company has manufacturing facilities in Brazil and India. It has presence in the US, Europe, South Africa, Japan, Brazil, and other emerging markets. Zydus Cadila is headquartered in Ahmedabad, Gujarat, India.

Cadila Healthcare Ltd (CADILAHC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cadila Healthcare Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Zydus Cadila Healthcare May Acquire 8 brands from Astrazeneca India 14

Zydus Healthcare Acquires Six Brands from Merck 15

Zydus Cadila Healthcare Acquires Rights to Melgain from Issar Pharma 16

Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 17

Zydus Cadila Healthcare to Acquire Actibile from Albert David for USD8.2 Million 18

Sentynl Therapeutics Acquires Abstral from Galena Biopharma 19

Private Equity 20

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 20

Partnerships 22

Zydus Cadila Healthcare to Enter into Agreement with Medicure International 22

Cadila Healthcare Enters into Agreement with Pharm Aid 23

Zydus Cadila Healthcare Enters into Agreement with Medicines for Malaria Venture 24

Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 25

Zydus Cadila and Eczacibasi Enter into Agreement 26

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27

Zydus Cadila Enters Into Co-Development Agreement With Pieris For Anticalin Therapeutics 28

IDRI And Zydus Cadila Healthcare Enter Into Agreement To Develop Vaccine Candidate For Visceral Leishmaniasis 30

Zydus Cadila On The Lookout For Partners To Market New Chemical Entity, Lipaglyn 31

Zydus Cadila To Terminate Co-Development Agreement With Eli Lilly 32

Licensing Agreements 33

Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 33

Zydus Cadila Healthcare Enters into Licensing Agreement with Neovii Biotech 34

Zydus Cadila Healthcare Enters into Licensing Agreement with Medicines Patent Pool 35

Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 36

Equity Offering 37

Cadila Healthcare to Raise Funds in Public Offering of Securities 37

Asset Transactions 38

Zydus Healthcare to Acquire India Human Formulations Undertaking from Cadila Healthcare for USD10.2 Million 38

Acquisition 39

Cadila Healthcare Acquires 51% Stake in Windlas Healthcare for USD22.5 Million 39

Zydus Cadila Healthcare Acquires Sentynl Therapeutics for USD171 Million 40

Zydus Cadila Healthcare To Sell Nippon Universal Pharma 41

Cadila Healthcare Ltd-Key Competitors 42

Cadila Healthcare Ltd-Key Employees 43

Cadila Healthcare Ltd-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Joint Venture 46

Recent Developments 48

Financial Announcements 48

May 25, 2018: Zydus Cadila's Net Profit up by 53% in Q4 48

Feb 08, 2018: Zydus Cadila's EBIDTA up by 108% in Q3 49

Feb 07, 2018: Zydus Wellness' Consolidated Net profit up by 43.8% in Q3 50

Nov 14, 2017: Zydus Cadila's EBIDTA up by 68% in Q2 51

May 27, 2017: Zydus Cadila registers Net Profit of Rs. 1488 crores in FY 17 52

Jan 31, 2017: Cadila Healthcare Announces Q3 results 53

Legal and Regulatory 54

Oct 09, 2018: Astrazeneca sues block Zydus Cadila bid generic nexium 54

Oct 04, 2018: Cadila Healthcare's manufacturing facility Zydus Biologics receives an Establishment Inspection Report from USFDA 55

Aug 29, 2018: Zydus Cadila: Update on USFDA inspection of injectables manufacturing facility of Liva Pharmaceuticals 56

Aug 29, 2018: Cadila Healthcare intimates of USFDA inspection of Liva Pharmaceuticals 57

Aug 24, 2018: Cadila Healthcare's Biologics manufacturing facility successfully completes USFDA inspection 58

Jun 06, 2018: Cadila Healthcare: USFDA inspection of wholly-owned subsidiary, Alidac Pharmaceuticals Ltd., located at SEZ, Ahmedabad 59

Mar 28, 2018: Cadila Healthcare announces successfully completion of USFDA inspection at Topical facility 60

Feb 09, 2018: Cadila Healthcare's Moraiya facility successfully completes USFDA inspection 61

Jan 19, 2018: Cadila Healthcare Announces Completion Of USFDA Inspection At Dabhasa, India Facility 62

Sep 07, 2017: Cadila Healthcare's Moraiya facility successfully completes USFDA inspection 63

Aug 29, 2017: Zydus receives EIR Report for Manufacturing Facility at the Pharma SEZ at Ahmedabad 64

Jun 21, 2017: Zydus receives EIR Report for Moraiya Manufacturing Facility 65

Apr 07, 2017: Cadila Healthcare Provides Update on US FDA Inspection at Changodar Manufacturing Facility 66

Feb 16, 2017: Cadila Healthcare Provides Update On USFDA Inspection Of Moraiya Facility 67

Product News 68

Nov 29, 2017: New diagnostic kits developed to detect rare and neglected infectious diseases 68

Clinical Trials 69

Nov 20, 2017: Zydus Oral Anemia Developmental Candidate, ZYAN1 Named as Desidustat by WHO 69

Jul 05, 2017: Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD 70

Appendix 71

Methodology 71

About GlobalData 71

Contact Us 71

Disclaimer 71


List Of Figure

List of Figures

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cadila Healthcare Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cadila Healthcare Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Cadila Healthcare Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Zydus Cadila Healthcare May Acquire 8 brands from Astrazeneca India 14

Zydus Healthcare Acquires Six Brands from Merck 15

Zydus Cadila Healthcare Acquires Rights to Melgain from Issar Pharma 16

Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 17

Zydus Cadila Healthcare to Acquire Actibile from Albert David for USD8.2 Million 18

Sentynl Therapeutics Acquires Abstral from Galena Biopharma 19

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 20

Zydus Cadila Healthcare to Enter into Agreement with Medicure International 22

Cadila Healthcare Enters into Agreement with Pharm Aid 23

Zydus Cadila Healthcare Enters into Agreement with Medicines for Malaria Venture 24

Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 25

Zydus Cadila and Eczacibasi Enter into Agreement 26

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27

Zydus Cadila Enters Into Co-Development Agreement With Pieris For Anticalin Therapeutics 28

IDRI And Zydus Cadila Healthcare Enter Into Agreement To Develop Vaccine Candidate For Visceral Leishmaniasis 30

Zydus Cadila On The Lookout For Partners To Market New Chemical Entity, Lipaglyn 31

Zydus Cadila To Terminate Co-Development Agreement With Eli Lilly 32

Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 33

Zydus Cadila Healthcare Enters into Licensing Agreement with Neovii Biotech 34

Zydus Cadila Healthcare Enters into Licensing Agreement with Medicines Patent Pool 35

Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 36

Cadila Healthcare to Raise Funds in Public Offering of Securities 37

Zydus Healthcare to Acquire India Human Formulations Undertaking from Cadila Healthcare for USD10.2 Million 38

Cadila Healthcare Acquires 51% Stake in Windlas Healthcare for USD22.5 Million 39

Zydus Cadila Healthcare Acquires Sentynl Therapeutics for USD171 Million 40

Zydus Cadila Healthcare To Sell Nippon Universal Pharma 41

Cadila Healthcare Ltd, Key Competitors 42

Cadila Healthcare Ltd, Key Employees 43

Cadila Healthcare Ltd, Other Locations 44

Cadila Healthcare Ltd, Subsidiaries 44

Cadila Healthcare Ltd, Joint Venture 46

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cadila Healthcare Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cadila Healthcare Ltd (Zydus Cadila) is an integrated, global healthcare provider. It discovers, develops, manufactures and markets various healthcare products. The company's product portfolio includes active pharmaceutical ingredients (APIs), formulations, wellness and animal health products. Zydus Cadila's products find application in the treatment of diseases in the therapeutic areas of gastrointestinal, cardiovascular, respiratory, pain management, cancer, inflammation, neurology, and women's health, among others. It conducts research to develop biologics, vaccines and new chemical entities. The company has manufacturing facilities in Brazil and India. It has presence in the US, Europe, South Africa, Japan, Brazil, and other emerging markets. Zydus Cadila is headquartered in Ahmedabad, Gujarat, India.

Cadila Healthcare Ltd (CADILAHC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cadila Healthcare Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Zydus Cadila Healthcare May Acquire 8 brands from Astrazeneca India 14

Zydus Healthcare Acquires Six Brands from Merck 15

Zydus Cadila Healthcare Acquires Rights to Melgain from Issar Pharma 16

Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 17

Zydus Cadila Healthcare to Acquire Actibile from Albert David for USD8.2 Million 18

Sentynl Therapeutics Acquires Abstral from Galena Biopharma 19

Private Equity 20

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 20

Partnerships 22

Zydus Cadila Healthcare to Enter into Agreement with Medicure International 22

Cadila Healthcare Enters into Agreement with Pharm Aid 23

Zydus Cadila Healthcare Enters into Agreement with Medicines for Malaria Venture 24

Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 25

Zydus Cadila and Eczacibasi Enter into Agreement 26

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27

Zydus Cadila Enters Into Co-Development Agreement With Pieris For Anticalin Therapeutics 28

IDRI And Zydus Cadila Healthcare Enter Into Agreement To Develop Vaccine Candidate For Visceral Leishmaniasis 30

Zydus Cadila On The Lookout For Partners To Market New Chemical Entity, Lipaglyn 31

Zydus Cadila To Terminate Co-Development Agreement With Eli Lilly 32

Licensing Agreements 33

Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 33

Zydus Cadila Healthcare Enters into Licensing Agreement with Neovii Biotech 34

Zydus Cadila Healthcare Enters into Licensing Agreement with Medicines Patent Pool 35

Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 36

Equity Offering 37

Cadila Healthcare to Raise Funds in Public Offering of Securities 37

Asset Transactions 38

Zydus Healthcare to Acquire India Human Formulations Undertaking from Cadila Healthcare for USD10.2 Million 38

Acquisition 39

Cadila Healthcare Acquires 51% Stake in Windlas Healthcare for USD22.5 Million 39

Zydus Cadila Healthcare Acquires Sentynl Therapeutics for USD171 Million 40

Zydus Cadila Healthcare To Sell Nippon Universal Pharma 41

Cadila Healthcare Ltd-Key Competitors 42

Cadila Healthcare Ltd-Key Employees 43

Cadila Healthcare Ltd-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Joint Venture 46

Recent Developments 48

Financial Announcements 48

May 25, 2018: Zydus Cadila's Net Profit up by 53% in Q4 48

Feb 08, 2018: Zydus Cadila's EBIDTA up by 108% in Q3 49

Feb 07, 2018: Zydus Wellness' Consolidated Net profit up by 43.8% in Q3 50

Nov 14, 2017: Zydus Cadila's EBIDTA up by 68% in Q2 51

May 27, 2017: Zydus Cadila registers Net Profit of Rs. 1488 crores in FY 17 52

Jan 31, 2017: Cadila Healthcare Announces Q3 results 53

Legal and Regulatory 54

Oct 09, 2018: Astrazeneca sues block Zydus Cadila bid generic nexium 54

Oct 04, 2018: Cadila Healthcare's manufacturing facility Zydus Biologics receives an Establishment Inspection Report from USFDA 55

Aug 29, 2018: Zydus Cadila: Update on USFDA inspection of injectables manufacturing facility of Liva Pharmaceuticals 56

Aug 29, 2018: Cadila Healthcare intimates of USFDA inspection of Liva Pharmaceuticals 57

Aug 24, 2018: Cadila Healthcare's Biologics manufacturing facility successfully completes USFDA inspection 58

Jun 06, 2018: Cadila Healthcare: USFDA inspection of wholly-owned subsidiary, Alidac Pharmaceuticals Ltd., located at SEZ, Ahmedabad 59

Mar 28, 2018: Cadila Healthcare announces successfully completion of USFDA inspection at Topical facility 60

Feb 09, 2018: Cadila Healthcare's Moraiya facility successfully completes USFDA inspection 61

Jan 19, 2018: Cadila Healthcare Announces Completion Of USFDA Inspection At Dabhasa, India Facility 62

Sep 07, 2017: Cadila Healthcare's Moraiya facility successfully completes USFDA inspection 63

Aug 29, 2017: Zydus receives EIR Report for Manufacturing Facility at the Pharma SEZ at Ahmedabad 64

Jun 21, 2017: Zydus receives EIR Report for Moraiya Manufacturing Facility 65

Apr 07, 2017: Cadila Healthcare Provides Update on US FDA Inspection at Changodar Manufacturing Facility 66

Feb 16, 2017: Cadila Healthcare Provides Update On USFDA Inspection Of Moraiya Facility 67

Product News 68

Nov 29, 2017: New diagnostic kits developed to detect rare and neglected infectious diseases 68

Clinical Trials 69

Nov 20, 2017: Zydus Oral Anemia Developmental Candidate, ZYAN1 Named as Desidustat by WHO 69

Jul 05, 2017: Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD 70

Appendix 71

Methodology 71

About GlobalData 71

Contact Us 71

Disclaimer 71


List Of Figure

List of Figures

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cadila Healthcare Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cadila Healthcare Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Cadila Healthcare Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Zydus Cadila Healthcare May Acquire 8 brands from Astrazeneca India 14

Zydus Healthcare Acquires Six Brands from Merck 15

Zydus Cadila Healthcare Acquires Rights to Melgain from Issar Pharma 16

Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 17

Zydus Cadila Healthcare to Acquire Actibile from Albert David for USD8.2 Million 18

Sentynl Therapeutics Acquires Abstral from Galena Biopharma 19

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 20

Zydus Cadila Healthcare to Enter into Agreement with Medicure International 22

Cadila Healthcare Enters into Agreement with Pharm Aid 23

Zydus Cadila Healthcare Enters into Agreement with Medicines for Malaria Venture 24

Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 25

Zydus Cadila and Eczacibasi Enter into Agreement 26

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27

Zydus Cadila Enters Into Co-Development Agreement With Pieris For Anticalin Therapeutics 28

IDRI And Zydus Cadila Healthcare Enter Into Agreement To Develop Vaccine Candidate For Visceral Leishmaniasis 30

Zydus Cadila On The Lookout For Partners To Market New Chemical Entity, Lipaglyn 31

Zydus Cadila To Terminate Co-Development Agreement With Eli Lilly 32

Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 33

Zydus Cadila Healthcare Enters into Licensing Agreement with Neovii Biotech 34

Zydus Cadila Healthcare Enters into Licensing Agreement with Medicines Patent Pool 35

Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 36

Cadila Healthcare to Raise Funds in Public Offering of Securities 37

Zydus Healthcare to Acquire India Human Formulations Undertaking from Cadila Healthcare for USD10.2 Million 38

Cadila Healthcare Acquires 51% Stake in Windlas Healthcare for USD22.5 Million 39

Zydus Cadila Healthcare Acquires Sentynl Therapeutics for USD171 Million 40

Zydus Cadila Healthcare To Sell Nippon Universal Pharma 41

Cadila Healthcare Ltd, Key Competitors 42

Cadila Healthcare Ltd, Key Employees 43

Cadila Healthcare Ltd, Other Locations 44

Cadila Healthcare Ltd, Subsidiaries 44

Cadila Healthcare Ltd, Joint Venture 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cadila Healthcare Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.